Immuneering Touts 64% 12-Month Survival for Atebimetinib in Pancreatic Cancer, Eyes Phase 3 [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
mGnP (median not yet reached, median follow-up 13.4 months), with supportive secondary endpoints including 8.5-month PFS (vs 5.5 benchmark), 39% ORR (vs 23%) and an 81% disease control rate The company is fully funded to start the global randomized Phase 3 MAPKeepeR-301 (atebimetinib + mGnP vs gemcitabine/nab-paclitaxel) with overall survival as the primary endpoint, a planned enrollment of 510 patients , first dosing expected mid-year and top-line readout in roughly two years. Immuneering positions atebimetinib as a novel “ Deep Cyclic Inhibitor ” that may improve survival by shrinking tumors durably, preserving body mass and minimizing side effects; the drug has tolerability driven adverse events mainly linked to chemotherapy, potential applicability across MAPK-driven cancers, and U.S. composition-of-matter patent protection into at least (possible extension to Interested in Immuneering Corporation? Here are five stocks we like better. Immuneering (NASDAQ:IMRX) Chief Execut
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering to Present at the Leerink Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present at the Leerink Global Healthcare ConferenceGlobeNewswire
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswire
- Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition [Yahoo! Finance]Yahoo! Finance
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- 2/5/26 - Form 4
- IMRX's page on the SEC website